Search Results - "Parker, Gregory S"

Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs by Firth, Amy L., Menon, Tushar, Parker, Gregory S., Qualls, Susan J., Lewis, Benjamin M., Ke, Eugene, Dargitz, Carl T., Wright, Rebecca, Khanna, Ajai, Gage, Fred H., Verma, Inder M.

“…Lung disease is a major cause of death in the United States, with current therapeutic approaches serving only to manage symptoms. The most common chronic and…”
Get full text

Structure-based Design of Pyridone–Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition by Reich, Siegfried H, Sprengeler, Paul A, Chiang, Gary G, Appleman, James R, Chen, Joan, Clarine, Jeff, Eam, Boreth, Ernst, Justin T, Han, Qing, Goel, Vikas K, Han, Edward Z. R, Huang, Vera, Hung, Ivy N. J, Jemison, Adrianna, Jessen, Katti A, Molter, Jolene, Murphy, Douglas, Neal, Melissa, Parker, Gregory S, Shaghafi, Michael, Sperry, Samuel, Staunton, Jocelyn, Stumpf, Craig R, Thompson, Peggy A, Tran, Chinh, Webber, Stephen E, Wegerski, Christopher J, Zheng, Hong, Webster, Kevin R

“…Dysregulated translation of mRNA plays a major role in tumorigenesis. Mitogen-activated protein kinase interacting kinases (MNK)­1/2 are key regulators of mRNA…”
Get full text

Abstract 1283: Discovery of selective and potent BRD4 protein degraders using Plexium's DELPhe platform by Parker, Gregory S., Toth, Julia A., Leriche, Geoffray, Bailey, Simon, Chng, Kenneth, Fish, Sara, Jamborcic, Aleks, Daniele, Elizabeth, Green, Erika, Hocker, Michael, Kallel, Adam, Thompson, Peggy A., Brown, Steven D., Vijayan, Kandaswamy

“…Targeted protein degradation using the endogenous Ubiquitin Proteasome System (UPS) represents a fundamentally new approach to drug discovery that potentially…”
Get full text

Abstract 3855: Inhibition of MNK by eFT508 reprograms T-cell signaling to promote an antitumor immune response by Stumpf, Craig R., Chen, Joan, Goel, Vikas K., Parker, Gregory S., Chiang, Gary G., Thompson, Peggy A., Webster, Kevin R.

“…Mitogen-activated protein (MAP) kinase signaling cascades play a vital role in T-cell activation upon antigen recognition. MNK1 and MNK2 are important…”
Get full text

Abstract 3399: Preclinical evaluation of eFT226, a potent and selective eIF4A inhibitor with anti-tumor activity in FGFR1,2 and HER2 driven cancers by Thompson, Peggy A., Young, Nathan P., Gerson-Gurwitz, Adina, Eam, Boreth, Goel, Vikas, Stumpf, Craig R., Chen, Joan, Parker, Gregory S., Fish, Sarah, Barrera, Maria, Sung, Eric, Staunton, Jocelyn, Chiang, Gary G., Webster, Kevin R.

“…Mutations or amplifications affecting receptor tyrosine kinases (RTKs) activate the RAS/MAPK and PI3K/AKT signaling pathways thereby promoting cancer cell…”
Get full text

Abstract B33: Targeting PI3K/mTOR signaling with potent, selective and orally-available small-molecule inhibitors of eIF4E by Parker, Gregory S., Hung, Ivy N.J., Staunton, Jocelyn, Barrera, Maria, Sung, Eric, Parra, Ana, Stumpf, Craig R., Chen, Joan, Thompson, Peggy A., Nevarez, Andreas, Wegerski, Christopher J., Clarine, Jeff, Sperry, Samuel, Xiang, Alan, Nilewski, Christian, Packard, Garrick K., Urklalan, Kaveri, Mukaiyama, Takasuke, Michels, Theo, Ernst, Justin T., Sprengeler, Paul A., Reich, Siegfried H., Chiang, Gary G., Webster, Kevin R.

“…Aberrant protein translation plays a role in the pathogenesis of multiple solid tumors and hematologic malignancies. The translation initiation factor eIF4E is…”
Get full text

Abstract 1302: Targeting hormone receptor-dependent cancers with potent, selective and orally-available small molecule inhibitors of eIF4E by Chiang, Gary G., Parker, Gregory S., Hung, Ivy N., Goel, Vikas K., Staunton, Jocelyn, Barrera, Maria, Sung, Eric, Parra, Ana, Stumpf, Craig R., Chen, Joan, Thompson, Peggy A., Nevarez, Andreas, Wegerski, Christopher J., Parker, Cody, Clarine, Jeff, Sperry, Samuel, Xiang, Alan, Nilewski, Christian, Packard, Garrick K., Urkalan, Kaveri, Mukaiyama, Takasuke, Michels, Theo, Ernst, Justin T., Sprengeler, Paul A., Reich, Siegfried H., Webster, Kevin R.

“…The PI3K/mTOR pathway is commonly dysregulated in many hormone receptor-dependent tumors and plays a key role in promoting tumor growth and mediating drug…”
Get full text

Abstract B133: eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers by Thompson, Peggy A, Young, Nathan P, Stumpf, Craig R, Eam, Boreth, Goel, Vikas K, Chen, Joan, Fish, Sarah, Parker, Gregory S, Gerson-Gurwitz, Adina, Barrera, Maria, Sung, Eric, Staunton, Jocelyn, Chiang, Gary G, Wegerski, Christopher J, Sperry, Samuel, Webster, Kevin R, Reich, Siegfried H

“…Background: Mutations or amplifications affecting receptor tyrosine kinases (RTKs) activate the RAS/MAPK and PI3K/AKT signaling pathways thereby promoting…”
Get full text

Abstract DDT02-05: eFT226: A selective and highly potent inhibitor of eukaryotic initiation factor 4A (eIF4A), a novel approach for the treatment of cancer by Reich, Siegfried H., Thompson, Peggy A., Ernst, Justin T., Eam, Boreth, Young, Nathan P., Fish, Sarah, Chen, Joan, Barrera, Maria, Howard, Haleigh, Parra, Ana, Sung, Eric, Staunton, Jocelyn, Hung, Ivy Nj, Parker, Gregory S., Chiang, Gary G., Wegerski, Christopher J., Nevarez, Andres, Clarine, Jeff, Sperry, Samuel, Xiang, Alan, Tran, Chinh, Nilewski, Christian, Packard, Garrick K., Michels, Theodore, Sprengeler, Paul A., Webster, Kevin R.

“…eFT226: A Selective and Highly Potent Inhibitor of Eukaryotic Initiation Factor 4A (eIF4A), a Novel Approach for the Treatment of Cancer Siegfried H Reich,…”
Get full text

Abstract 421: PLX-3618, a potent, selective monovalent BRD4 degrader demonstrates activity in models of prostate cancer by Steadman, Kenneth, Parker, Gregory S., Leriche, Geoffray, Fish, Sarah, Toth, Julia, Spalding, Mary E., Daniele, Elizabeth, Jamborcic, Aleksandar, Li, Xiaoming, Kallel, E Adam, Barmare, Farhana, Chng, Kenneth, Green, Erika, Hocker, Michael, Imler, Elliot, Zhang, Yi, Thompson, Peggy A., Bailey, Simon

“…Prostate cancer is the second most common cause of cancer related deaths in men in the United States. Pathogenesis is driven by the androgen receptor (AR),…”
Get full text

Abstract 596: eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity by Webster, Kevin R., Goel, Vikas K., Staunton, Jocelyn, Stumpf, Craig R., Sharma, Rajesh, Hung, Ivy N., Parker, Gregory S., Molter, Jolene, Chiang, Gary G., Wegerski, Christopher J., Sperry, Samuel, Huang, Vera, Chen, Joan, Thompson, Peggy A., Tran, Chinh, Ernst, Justin T., Sprengeler, Paul A., Reich, Siegfried H.

“…Dysregulated translation of messenger RNA (mRNA) plays a role in the pathogenesis of multiple solid tumors and hematological malignancies. MNK1 and MNK2…”
Get full text

Abstract PR11: eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade by Webster, Kevin R., Goel, Vikas K., Staunton, Jocelyn, Hung, Ivy NJ, Parker, Gregory S., Stumpf, Craig R., Molter, Jolene, Chiang, Gary G., Wegerski, Christopher J., Sperry, Samuel, Chen, Joan, Huang, Vera, Thompson, Peggy A., Tran, Chinh, Ernst, Justin T., Webber, Stephen E., Sprengeler, Paul A., Reich, Siegfried H.

“…Purpose: This study was designed to evaluate the potential of eFT508 to selectively regulate key immune signaling pathways and enhance anti-tumor immunity as a…”
Get full text

eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL) by Webster, Kevin R., Goel, Vikas K, Hung, Ivy NJ, Parker, Gregory S, Staunton, Jocelyn, Neal, Melissa, Molter, Jolene, Chiang, Gary G, Jessen, Katti A., Wegerski, Christopher J, Sperry, Samuel, Huang, Vera, Chen, Joan, Thompson, Peggy A, Appleman, James R, Webber, Stephen E, Sprengeler, Paul A, Reich, Siegfried H

“…Dysregulated translation of messenger RNA (mRNA) plays a role in the pathogenesis of multiple solid tumors and hematological malignancies. MNK1 and MNK2…”
Get full text